Exploring the molecular mechanisms underlying α- and β-cell dysfunction in diabetes

Area of Science:

• Endocrinology and Metabolism
• Cell Biology
• Molecular Medicine

Background:

• Pancreatic islet dysfunction, characterized by impaired insulin secretion (beta cells) and dysregulated glucagon secretion (alpha cells), is central to diabetes.
• Chronic hyperglycemia induces oxidative stress, leading to pancreatic beta-cell dysfunction via PDX1 transcription factor alteration.
• Insulin signaling plays a critical role in regulating both alpha and beta cell function.

Purpose of the Study:

• To elucidate the molecular mechanisms underlying pancreatic islet dysfunction in diabetes.
• To investigate the role of insulin signaling in both alpha and beta cell pathophysiology.
• To explore the therapeutic potential of GLP-1 for diabetes.

Main Methods:

• Investigated transcription factor PDX1 nucleocytoplasmic translocation in beta cells under hyperglycemic conditions.
• Utilized alpha-cell-specific insulin receptor knockout mice to study alpha-cell function.
• Examined glucagon secretion in response to high glucose in cell lines and isolated islets.

Main Results:

• Disordered insulin signaling is a key factor in the pathophysiology of both alpha and beta cell dysfunction in diabetes.
• PDX1 dysfunction in beta cells is linked to oxidative stress and altered signaling pathways.
• Alpha-cell-specific insulin receptor knockout mice showed impaired glucagon secretion.
• High glucose directly stimulated glucagon secretion and impaired insulin signaling in islets.

Conclusions:

• Disordered insulin signaling is a unifying mechanism in pancreatic islet dysfunction contributing to diabetes.
• GLP-1 demonstrates therapeutic potential for diabetes by beneficially affecting dysfunctional alpha and beta cells.
• Understanding these molecular mechanisms provides insights for developing novel diabetes therapies.